{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:38:20Z","timestamp":1793191100363,"version":"4.5.0"},"reference-count":33,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Today, single-inhaler ICS\/LAMA\/LABA (SITT) COPD therapies are available. It is unclear whether they are more effective than multiple-device triple therapies (MITT) in improving COPD outcomes. Methods: We retrospectively considered patients on SITT\/MITT in 2019\/2020 who were prescribed &gt;7 packages of ICS\/LABA\/LAMA or ICS\/LAMA (+LAMA). The two treatments were compared concerning systemic corticosteroids, antibiotics, salbutamol, antifungal prescriptions, and number of emergency room visits\/hospitalizations (ERV\/Hs). We studied 292 MITT patients (Group A) during 2019, switching to SITT in 2020, and 366 subjects (Group B) who took SITT during 2019, and 206 MITT individuals (Group C) in 2020. Results: ICS\/LABA + LAMA (MITT) package use was 8.2 \u00b1 4.2 and 7.85 \u00b1 4 in 2019, switching to 11.2 \u00b1 3.2 when patients shifted to SITT in 2020 (p = 0.0001). Group A MITT package use was lower than in SITT patients in 2019 (9.31 \u00b1 2.71, p = 0.0001; Group B). Throughout 2020, Group C (10.3 \u00b1 6.1 packs) adherence to ICS\/LABA was similar to SITT adherence in Group A (p = 0.270), whereas LAMA package use (9.1 \u00b1 5) was lower (p = 0.0038). Patients using systemic corticosteroids\/antibiotics were fewer in SITT in 2020, compared to the MITT results in 2019. Subjects with fewer ERV\/Hs were observed with SITT rather than with MITT. Particularly, 13.8% of patients needed \u22652 ERV\/Hs when treated with SITT, whereas 19.2% needed \u22652 ERV\/Hs with MITT in 2019 (p = 0.08). Multivariate analysis, adjusted for all confounding factors including treatment adherence, showed that MITT (vs. SITT) can have an increased risk of at least one ERV\/H (subjects receiving MITT during 2019 passing to SITT in 2020, OR: 1.718 [1.010\u20132.924], p = 0.046; Group A\/MITT\/2019 vs. Group B\/SITT\/2019, OR: 1.650 [0.973\u20133.153], p = 0.056; Group C\/MITT\/2020 vs. Group B\/SITT\/2019, OR: 1.908 [1.018\u20133.577], p = 0.044). Conclusions: SITT therapy may promote treatment adherence more effectively, therefore, reducing COPD exacerbations better than MITT. A possible synergistic effect of ICS\/LABA\/LAMA intake with a single device might be another cause of SITT\u2019s greater efficacy.<\/jats:p>","DOI":"10.3390\/jcm13206191","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T09:14:03Z","timestamp":1729156443000},"page":"6191","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Triple Therapy in COPD in Real Life: Is It Better to Use Single or Multiple Inhalers?"],"prefix":"10.3390","volume":"13","author":[{"given":"Bruno","family":"Sposato","sequence":"first","affiliation":[{"name":"Pneumology Department, Local Health Unit \u2018Sud-Est\u2019, \u2018Misericordia\u2019 Hospital, 58100 Grosseto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1718-1587","authenticated-orcid":false,"given":"Alberto","family":"Ricci","sequence":"additional","affiliation":[{"name":"Division of Pneumology, Department of Clinical and Molecular Medicine, Sapienza University of Rome, AOU Sant\u2018Andrea, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9315-1654","authenticated-orcid":false,"given":"Leonardo Gianluca","family":"Lacerenza","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Medicine, Local Health Unit \u2018Sud-Est\u2019, \u2018Misericordia\u2019 Hospital, 58100 Grosseto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Petrucci","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Medicine, Local Health Unit \u2018Sud-Est\u2019, \u2018Misericordia\u2019 Hospital, 58100 Grosseto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2328-8943","authenticated-orcid":false,"given":"Alberto","family":"Cresti","sequence":"additional","affiliation":[{"name":"Cardiology Department, Local Health Unit \u2018Sud-Est\u2019, \u2018Misericordia\u2019 Hospital, 58100 Grosseto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Baratta","sequence":"additional","affiliation":[{"name":"Cardiology Department, Local Health Unit \u2018Sud-Est\u2019, \u2018Misericordia\u2019 Hospital, 58100 Grosseto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Perrella","sequence":"additional","affiliation":[{"name":"Pneumology Department, Local Health Unit \u2018Sud-Est\u2019, \u2018Misericordia\u2019 Hospital, 58100 Grosseto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Serafini","sequence":"additional","affiliation":[{"name":"Medical Management Department, Local Health Unit \u2018Sud-Est\u2019, \u2018Misericordia\u2019 Hospital, 58100 Grosseto, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7470-2422","authenticated-orcid":false,"given":"Marco","family":"Scalese","sequence":"additional","affiliation":[{"name":"Institute of Clinical Physiology, Italian National Research Council, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"key":"ref_1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2023, March 01). Global Strategy for the Diagnosis, Management and Prevention of COPD. Available online: http:\/\/goldcopd.org\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"k4388","DOI":"10.1136\/bmj.k4388","article-title":"Triple therapy in the management of chronic obstructive pulmonary disease: Systematic review and meta-analysis","volume":"363","author":"Zheng","year":"2018","journal-title":"BMJ"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/17476348.2020.1816830","article-title":"Evaluating triple ICS\/LABA\/LAMA therapies for COPD patients: A network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies","volume":"15","author":"Calzetta","year":"2021","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","article-title":"Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): A double-blind, parallel group, randomised controlled trial","volume":"388","author":"Singh","year":"2016","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","article-title":"Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): A double-blind, parallel group, randomised controlled trial","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"00950-2020","DOI":"10.1183\/23120541.00950-2020","article-title":"INTREPID: Single- versus multiple-inhaler triple therapy for COPD in usual clinical practice","volume":"7","author":"Halpin","year":"2021","journal-title":"ERJ Open Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12931-018-0724-0","article-title":"Single-inhaler fluticasone furoate\/umeclidinium\/vilanterol versus fluticasone furoate\/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: A randomized non-inferiority study","volume":"19","author":"Bremner","year":"2018","journal-title":"Respir. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12931-020-01360-w","article-title":"Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: Lung function and health status results from two replicate randomized controlled trials","volume":"21","author":"Ferguson","year":"2020","journal-title":"Respir. Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Resta, E., Scioscia, G., Lacedonia, D., Quarato, C.M.I., Panza, F., Resta, O., Lepore, G., Buonamico, E., Di Lecce, V., and Carpagnano, G.E. (2022). Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region. BMC Health Serv. Res., 22.","DOI":"10.1186\/s12913-022-08640-9"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.2147\/COPD.S370577","article-title":"Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial","volume":"17","author":"Halpin","year":"2022","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Lin, L., Liu, C., Cheng, W., Song, Q., Zeng, Y., Li, X., Deng, D., Liu, D., Chen, Y., and Cai, S. (2023). Comparison of treatment persistence, adherence, and risk of exacerbation in patients with COPD treated with single-inhaler versus multiple-inhaler triple therapy: A prospective observational study in China. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1147985"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(17)30188-5","article-title":"Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): A double-blind, parallel group, randomised controlled trial","volume":"389","author":"Vestbo","year":"2017","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"17534666221081047","DOI":"10.1177\/17534666221081047","article-title":"Mortality, seasonal variation, and susceptibility to acute exacerbation of COPD in the pandemic year: A nationwide population study","volume":"16","author":"Sarc","year":"2022","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1164\/rccm.202110-2389CI","article-title":"A Pandemic Lesson for Global Lung Diseases: Exacerbations Are Preventable","volume":"205","author":"Cookson","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"106085","DOI":"10.1016\/j.rmed.2020.106085","article-title":"Significant reduction in hospital admissions for acute exacerbation of chronic obstructive pulmonary disease in Hong Kong during coronavirus disease 2019 pandemic","volume":"171","author":"Chan","year":"2020","journal-title":"Respir. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/aje\/kwab292","article-title":"Social Distancing in Relation to Severe Exacerbations of Chronic Obstructive Pulmonary Disease: A Nationwide Semi-Experimental Study During the COVID-19 Pandemic","volume":"191","author":"Saeed","year":"2022","journal-title":"Am. J. Epidemiol."},{"key":"ref_18","first-page":"572","article-title":"Decrease in Exacerbations During the Coronavirus Disease 2019 Pandemic in a Cohort of Veterans with COPD","volume":"8","author":"Trujillo","year":"2021","journal-title":"Chronic. Obstr. Pulm. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"00718-2020","DOI":"10.1183\/23120541.00718-2020","article-title":"COPD in the time of COVID-19: An analysis of acute exacerbations and reported behavioural changes in patients with COPD","volume":"7","author":"McAuley","year":"2021","journal-title":"ERJ Open Res."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Suh, H.S., Chang, M.S., Yu, I., Park, S., Lee, J.H., Lee, S.J., Lee, W.Y., Yong, S.J., and Kim, S.H. (2022). Adherence to Long-Acting Inhaler Use for Initial Treatment and Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Retrospective Cohort Study. J. Pers. Med., 12.","DOI":"10.21203\/rs.3.rs-1825891\/v1"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12931-019-1219-3","article-title":"Does a tailored intervention to promote adherence in patients with chronic lung disease affect exacerbations? A randomized controlled trial","volume":"20","author":"Gregoriano","year":"2019","journal-title":"Respir. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.rmed.2010.09.006","article-title":"Treatment of COPD: Relationships between daily dosing frequency, adherence, resource use, and costs","volume":"105","author":"Toy","year":"2011","journal-title":"Respir. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"106724","DOI":"10.1016\/j.rmed.2021.106724","article-title":"Determining factors associated with inhaled therapy adherence on asthma and COPD: A systematic review and meta-analysis of the global literature","volume":"191","author":"Monteiro","year":"2022","journal-title":"Respir. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/crj.13190","article-title":"Adherence to COPD free triple inhaled therapy in the real world: A primary care based study","volume":"14","author":"Zucchelli","year":"2020","journal-title":"Clin. Respir. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2147\/COPD.S392946","article-title":"Impact of Medication Adherence on Emergency Department Visits in Patients with COPD in a Single Tertiary Hospital in Saudi Arabia","volume":"18","author":"Alshehri","year":"2023","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"00325","DOI":"10.1183\/23120541.00325-2019","article-title":"Predicting and preventing hospital readmission for exacerbations of COPD","volume":"6","author":"Kong","year":"2020","journal-title":"ERJ Open Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/thx.2009.113662","article-title":"Adherence to inhaled therapy, mortality and hospital admission in COPD","volume":"64","author":"Vestbo","year":"2009","journal-title":"Thorax"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.coph.2018.03.011","article-title":"Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy","volume":"40","author":"Calzetta","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1007\/s12325-019-01119-w","article-title":"Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients","volume":"36","author":"Calzetta","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"102076","DOI":"10.1016\/j.pupt.2021.102076","article-title":"Which LABA\/LAMA should be chosen in COPD patients in real life?","volume":"71","author":"Sposato","year":"2021","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/bph.14909","article-title":"Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo","volume":"177","author":"Rogliani","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.2147\/COPD.S342244","article-title":"Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial","volume":"17","author":"Gabrio","year":"2022","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/17476348.2022.2145951","article-title":"Cost-effectiveness of single-inhaler triple therapy for patients with severe COPD: A systematic literature review","volume":"16","author":"Rana","year":"2022","journal-title":"Expert Rev. Respir. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/20\/6191\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:15:21Z","timestamp":1760112921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/20\/6191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":33,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["jcm13206191"],"URL":"https:\/\/doi.org\/10.3390\/jcm13206191","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,17]]}}}